The US regulator is also reviewing a supplemental new drug application for VTAMA cream as a potential treatment for atopic dermatitis. Credit: iced.espresso/Shutterstock.

Organon has completed the acquisition of Dermavant Sciences, a subsidiary of Roivant, expanding its dermatology portfolio.

With the deal’s closure, Organon has added Dermavant’s VTAMA (tapinarof) cream 1%, a US Food and Drug Administration (FDA)-approved nonbiologic, non-steroidal topical treatment, to its portfolio.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

VTAMA cream 1% is indicated for use in adults with mild, moderate, or severe plaque psoriasis.

The US regulator is also reviewing a supplemental new drug application (sNDA) for VTAMA cream as a potential treatment for atopic dermatitis (AD) in adults and children aged two years and older.

A decision on the approval for this indication is expected by the fourth quarter of 2024.

As per the acquisition deal signed in September 2024, Dermavant is eligible to receive up to $1.2bn from Organon. The sum includes an upfront payment of $175m and a $75m in milestone payment upon regulatory approval for the Dermavant asset.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Organon will also make additional payments of up to $950m on meeting commercial milestones, as well as tiered royalties on net product sales to Dermavant shareholders.

Organon CEO Kevin Ali stated: “The future of dermatology depends on innovative treatments like VTAMA, and Organon’s acquisition of Dermavant allows us to further expand our existing portfolio of established brands and biosimilar dermatology treatments.

“We are excited to bring this nonbiologic non-steroidal topical option to the millions of patients suffering from a chronic skin condition like plaque psoriasis and, potentially in the future, atopic dermatitis.”

The rights to VTAMA cream are owned by Dermavant globally, excluding China, with Japan’s rights already out-licensed.

Organon will also assume Dermavant liabilities, valued at approximately $286m as reported by Roivant as of 30 June 2024, subject to fair value accounting adjustments.

Legal and financial advisories for the transaction were provided by Freshfields Bruckhaus Deringer and Goldman Sachs & Co for Roivant and Covington & Burling for Organon.